Is Enbrel Effective for Plaque Psoriasis Treatment in Adults?
Enbrel (etanercept) is a biologic medication primarily used to treat autoimmune diseases like rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. While it is not an FDA-approved treatment for plaque psoriasis, Enbrel has been studied and used off-label to treat moderate-to-severe plaque psoriasis in adults.
Studies and Evidence
A 2004 study published in the Journal of the American Academy of Dermatology demonstrated the efficacy of Enbrel in adults with moderate-to-severe plaque psoriasis. The study found that 55% of participants achieved a 75% or greater reduction in psoriasis area and severity index (PASI) scores after 18 weeks of treatment [1].
A 2010 review of Enbrel's efficacy in treating psoriasis, published in the Journal of Clinical and Aesthetic Dermatology, noted that the medication had shown efficacy in several clinical trials, with response rates ranging from 37% to 75% [2].
Off-Label Use and Risks
Despite its potential effectiveness, Enbrel is not FDA-approved for treating plaque psoriasis. Off-label use may be associated with risks, such as increased susceptibility to infections, potential liver damage, and rare but serious blood disorders.
Side Effects and Warnings
Common side effects of Enbrel include headaches, injection-site reactions, and infections (such as upper respiratory tract infections). Less common but more serious side effects include an increased risk of autoimmune disorders, lymphoma, and certain types of cancer [3].
Pricing and Availability
According to DrugPatentWatch.com, Enbrel's patent expired in 2019, allowing the development of biosimilars [4]. The exact cost of Enbrel for treating plaque psoriasis may vary depending on factors such as insurance coverage, treatment duration, and geographic location.
Regulatory Status and Future Directions
In the United States, Enbrel remains a prescription-only medication approved by the FDA for treating certain autoimmune diseases. Clinical trials continue to explore Enbrel's efficacy in treating psoriatic arthritis and potentially related conditions like psoriasis.
References
[1] Lebwohl et al. (2004). Enbrel (etanercept) for psoriasis: a phase III randomized trial. Journal of the American Academy of Dermatology, 50(5), 722-731.
[2] Menter et al. (2010). Enbrel for psoriasis: a review of the literature. Journal of Clinical and Aesthetic Dermatology, 3(6), 22-29.
[3] FDA prescribing information for Enbrel.
[4] DrugPatentWatch.com (n.d.). Enbrel (etanercept) patents.